| abstract |
Provided are applications as a breast cancer diagnosis and indication marker of a CST1 gene spliceosome expressed by SEQ ID NO. 48 and of a CST1 gene-encoded protein, Cystatin-SN, expressed by SEQ ID NO. 52. By determining the expression level of the marker, differential diagnosis and/or susceptibility analysis are allowed for breast cancer or breast cancer tissue metastases, assessments of a therapeutic medicament, of a treatment, of therapeutic efficacy, and of prognosis are allowed for breast cancer or breast cancer tissue metastases, breast cancer or breast cancer tissue metastasis prevalence risk assessment is allowed for a relevant group, while provided are the advantages of high sensitivity, great specificity, and accurate and reliable result. Provided in addition are applications of a trapping agent of the CST1 gene spliceosome and of a trapping agent of Cystatin-SN in preparing a breast cancer diagnosis and indication test reagent, reagent testing kit, and chip; also provided are the breast cancer diagnosis and indication reagent testing kit and chip having the trapping agent of CST1 gene spliceosome and the trapping agent of Cystatin-SN. |